Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Buy Rating

Haemonetics (NYSE:HAE) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other equities analysts have also commented on HAE. Weiss Ratings lowered shares of Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday. Barrington Research dropped their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Mizuho dropped their target price on shares of Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and an average target price of $77.11.

Haemonetics Price Performance

HAE stock opened at $65.48 on Friday. The firm has a 50 day moving average of $58.23 and a 200-day moving average of $67.09. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The firm has a market capitalization of $2.98 billion, a P/E ratio of 32.42, a price-to-earnings-growth ratio of 1.25 and a beta of 0.53.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The company had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. During the same period last year, the business earned $1.24 earnings per share. Haemonetics’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts predict that Haemonetics will post 5.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. raised its stake in shares of Haemonetics by 1,405.7% during the third quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after acquiring an additional 43,042 shares in the last quarter. Isthmus Partners LLC raised its stake in shares of Haemonetics by 36.5% during the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after acquiring an additional 16,505 shares in the last quarter. Invenomic Capital Management LP raised its stake in shares of Haemonetics by 1,691.5% during the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after acquiring an additional 470,502 shares in the last quarter. Skylands Capital LLC raised its stake in shares of Haemonetics by 195.4% during the third quarter. Skylands Capital LLC now owns 81,369 shares of the medical instruments supplier’s stock worth $3,966,000 after acquiring an additional 53,819 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Haemonetics by 16.5% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 559,972 shares of the medical instruments supplier’s stock worth $27,293,000 after acquiring an additional 79,138 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.